MRI Interventions and Clinical Laserthermia Systems (CLS) Announce Collaboration to Develop Next-Generation Navigation and Laser Ablation Platforms for Neurosurgery
Under the terms of the agreement, MRIC acquires worldwide exclusive rights to the platform for use in Neurosurgery and Spine with CLS as manufacturer
IRVINE, Calif. and LUND, Sweden, Oct. 17, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) and Clinical Laserthermia Systems AB (NASDAQ FIRST NORTH:CLS B) today entered into a collaborative license and co-development agreement to provide next-generation navigation and laser ablation platforms for use in Spine and Neurosurgery. Under the terms of the agreement, CLS will provide an exclusive, worldwide license to current and future products and IP to MRI Interventions and will act as the exclusive manufacturer of those products. CLS will retain the rights for all fields outside of Neuro and Spine.
“This agreement is a truly exciting step towards execution of our four-pillar growth strategy,” commented Joe Burnett, President and CEO of MRI Interventions. “Historically we have been the company that helps deliver other company’s therapeutic products to deep structures of the brain in the most precise manner possible. Now we have the opportunity to deliver our own therapies, which will improve efficiency, workflow and procedure times for our hospital customers, and expand revenue and per-procedure profitability for our investors. Now in partnership with CLS, we can truly be a leader in the movement toward minimally-invasive neurosurgery because we can offer both navigation and laser ablation therapy, all under the watchful eye of a single clinical specialist to help support the procedure.”
“We are delighted to find a partner to bring our advanced laser ablation platform to the neurosurgery space,” added Lars-Erik Eriksson, President and CEO of CLS. “The neurosurgery market is an incredibly challenging market to enter and build from the ground up. We are thrilled to be able to find a partner in MRI that already has years of experience in the space, a large and growing installed base at some of the most prestigious neurosurgery centers in the U.S., and a team of clinical specialists already participating in the guidance of these laser surgeries today. This allows us to leave our technology in MRI’s experienced hands in neuro, while maintaining control of high precision laser ablation elsewhere in the body including Prostate, Urology and more.”
TRANBERG® | Thermal Therapy System is a laser system with USFDA 510 (k) clearance for soft tissue ablation and in Europe (CE mark) for soft tissue ablation and immunostimulatory interstitial laser thermotherapy (imILT®).
“Our number one priority will always be our patients,” continued Mr. Burnett. “We will innovate and develop new products and workflows in collaboration with CLS until we have a platform that provides accuracy and workflow advantages to our customers and meets our requirements of being able to do multiple procedures in the same day. We estimate a formal launch of this combined platform sometime in 2020. Given the advanced development and regulatory status of the Tranberg system, we see the development costs in 2019 as more of a re-prioritization of existing resources than a large operating investment. Moreover, we expect this partnership to improve profitability in 2020 given the added therapy revenue MRI will see on the top line with minimal added distribution costs through our existing sales channel and support network. In no way will this agreement impact our commitment to support hospitals using laser ablation technology from other providers as we strongly believe these technologies are essential to making minimally-invasive neurosurgery the new standard, and the preferred pathway for patients.”
Investors and analysts are invited to listen to a live broadcast discussion of the Company's announcement on Friday, October 19, 2018, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) that may be accessed by visiting the Company's website at www.mriinterventions.com and selecting “Investors” / “News” / “IR Calendar.” Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until November 2, 2018 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at www.mriinterventions.com, on the “Investor Relations” page.
About MRI Interventions, Inc.
Building on the power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
About Clinical Laserthermia Systems AB
The company is developing TRANBERG® | Thermal Therapy System for precise, safe and effective minimally invasive ablation of soft tissues including immune stimulating thermal therapy (imILT®) of solid cancerous tumors. The products have received 510(k) clearance and are CE marked. The company, which is headquartered in Lund, Sweden, has subsidiaries in Germany and USA. For more information, please visit www.clinicallaser.com.
Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company’s ability to obtain additional financing; estimates regarding the sufficiency of the Company’s cash resources; future revenues from sales of the company’s ClearPoint Neuro Navigation System products; and the company’s ability to market, commercialize and achieve broader market acceptance for the company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the company’s actual results are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2017, and its Quarterly Report on Form 10-Q for the three months ended June 30, 2018, both of which have been filed with the Securities and Exchange Commission.
Contact Information MRI Interventions Inc:
Matt Kreps, Darrow Associates Investor Relations
+1 (214) 597-8200
Contact Information Clinical Laserthermia Systems AB:
+46 70 290 33 00